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Million-Dollar Ideas
Michelson Prize and Grants program spurs research into nonsurgical spay/neuter

The tools of the spay/neuter trade might be changing. The Michelson Prize and Grants program is putting up millions of dollars to inspire
researchers to devise a nonsurgical alternative to conventional surgery.

Of course it can’t buy you love, and it
may be the root of all evil, but on this we can
agree: Money can get things done.
It might, in fact, spur a solution to pet
overpopulation and unnecessary euthanasia.
That’s the hope of the Found Animals
Foundation, a Los Angeles-based nonprofit
founded by Gary Michelson, a billionaire spinal surgeon who made his fortune patenting
medical devices. Incorporated in 2005 after
Michelson saw the animal issues caused by
Hurricane Katrina and was moved to help,
Found Animals offers a variety of programs,
from adoption to pet identification, aimed at
minimizing or ending shelter euthanasia. (The
“found” in the organization’s name, says
executive director Aimee Gilbreath, reflects
both the promise of its microchip program

and Michelson’s affection
fo r t h e s o ng “A ma zing
Grace,” which includes the
line, “I once was lost, but
now am found.”)
In late 2008, the foundation announced an eyepopping brass ring : the
Michelson Prize and Grants
in Reproductive Biology. The
prize promised $25 million
to the first entity to develop
a low-cost, single-dose, nonsurgical method of
permanently sterilizing cats and dogs. The project made another $50 million available in grants
for related research. “The prize is out there to
motivate people to go after the Holy Grail, and
the grant program is there to make sure they

have the resources to pursue
that lofty goal,” Gilbreath
says. She’s confident the
prize will be awarded within
five years, but notes it will
take at least another two
years beyond that to get a
product on the market.
In the edited interview
that follows, Gilbreath, a
former biotechnology researcher and business consultant who became the foundation’s first
employee, and Shirley Johnston, an expert on
animal reproduction who oversees the prize
and grants program, discuss the project’s
progress with Animal Sheltering associate
editor James Hettinger.
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Michael Munks didn’t hear about
the Michelson Prize and Grants
through a science journal or a grants
website. He got the word from a
decidedly less academic source.
“Crazily enough, I first heard
about this when I was watching
Saturday Night Live.” On a “Weekend
Update” segment in October 2008,
“they were mentioning that Gary
Michelson was offering this $75 million prize and grants for nonsurgical
sterilization of cats and dogs,” he
recalls. “So then they were making a
joke about how the cats and dogs had
put together $100 million to hire a hit
man to take out Gary Michelson.”
But for Munks, an immunologist and research fellow who studies
viruses and the immune system’s
response to them at National Jewish
Health in Denver, the thought of applying the concept of immunocontraception to cats and dogs was no joke.
He put together a proposal and in late
2009 got a four-year Michelson grant
for more than $700,000.
The idea of immunocontraception,
Munks explains, is to trick the immune
system into deactivating part of the
reproductive system. If you can create
an immune response that inactivates
the eggs or the hormones that regulate reproduction, you can essentially
“use the animal’s immune system to
sterilize itself,” he says.
Munks is proposing a herpesvirus
to create a nonsurgical sterilant for cats
and dogs—an approach he says other
researchers found effective in mice.

Michael Munks
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Shirley Johnston acknowledges that developing
a nonsurgical way to permanently disable
the reproductive systems of cats and dogs
is a difficult task, but she’s impressed with
the quality of the proposals received by the
Michelson Prize and Grants program.

Executive director Aimee Gilbreath says the
Found Animals Foundation—reflecting the
wishes of its founder, Gary Michelson—
seeks innovative solutions to the problem of
shelter euthanasia.

Animal Sheltering: Give us a thumbnail
description of the Michelson Prize and
Grants program.
Aimee Gilbreath: When [Gary Michelson]
got interested in how to keep so many pets
from being euthanized in shelters, he started
looking at weak points in the system, and
realized that affordability and accessibility
of spay and neuter was an issue. He started
thinking that technology has got to have a
solution to this that is nonsurgical, affordable, and easy to deploy in a field setting.
That was the genesis of the Michelson Prize
and Grants program.

about 15 proposals. And we’ve got funding
in place around the United States, and also in
Argentina and Australia—researchers there
that have successfully applied for our grants.

Shirley Johnston: In the history of the world,
there has never been such [an] amount of
money available to study dog and cat reproduction. Our program is trying to get the word
out to not only scientists who have worked
in the field of dog and cat reproduction in
the past, but also people that work on basic
cellular mechanisms, people that work in
human reproduction, to try and find innovative ways that we can discover a single-dose,
nonsurgical sterilant. To date we’ve approved
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What form are you envisioning?
Would this be a shot? A pill?
Gilbreath: We actually try really hard to be
agnostic about what approach might ultimately carry the day. We are open to any
nonsurgical method, whether that would be
an injectable, a pill, some sort of medical device, some sort of very small implant. We really don’t have a preconceived notion of how
this problem gets solved.
Do you think this will ultimately be
cheaper than conventional surgery?
Gilbreath: That is our hope, and one of the
requirements for winning the prize is that it
has a reasonable manufacturing cost.
How affordable do you think this
would be?
Johnston: We hope that it will be in the
neighborhood of $5 to $10 [per dose] when
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Seeking a ‘Magic Bullet’
manufactured on a large scale. We are prepared to award the prize for something up to
about $30.
Are you picturing a day when this nonsurgical method would actually replace
conventional surgeries?
Gilbreath: It’s not necessarily our intention to
replace surgical spay/neuter. It’s our intention
to extend the reach to places and to people
where surgical techniques don’t work well
now. You could envision a product coming
out of this—just for example—that was great
for feral cats, but maybe not great for owned
cats. It could be that owned cats will continue
to get surgical spay and neuter, but there’ll be
a great option for feral cat caretakers.
What do you see as the obstacles to this
nonsurgical solution? Is it a scientific
problem, or a matter of the funding not
being there to do the research?

His lab might focus on tiny fruit flies, but
William Ja is thinking big.
Normally, he uses fruit flies to study
human aging, nutrition, and disease.
And now Ja has diversified to join the
researchers seeking a nonsurgical sterilant
for dogs and cats through the Michelson
project, which awarded him a two-year
grant of more than $200,000.
Ja, an assistant professor at Scripps
Research Institute in Jupiter, Fla., recalls
thinking the prize money was “amazing”
when he spotted a Michelson program ad
in a scientific journal in late 2008. He and
some colleagues jokingly kicked around
some ideas over dinner. It was the kind of
talk that often ends at the table, but Ja
decided to investigate further.
Borrowing from cancer research, he
eventually pitched the Michelson funders
the idea of developing a “magic bullet”
(technically a toxin-ligand conjugate) that
would target crucial reproductive cells

William Ja

in the gonads of cats and dogs, causing
sterilization.
Ja acknowledges that developing a
single drug that permanently takes out
male and female reproduction in two different species is a daunting task, but he
is confident that someone will devise at
least a partial solution to the Michelson
program’s challenge. “I think it should
be doable, given the examples of sterility
that occur in nature,” he says. “… And
certainly this giant load of cash will help
the field greatly.”
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At Crinetics
Pharmaceuticals,
Scott Struthers
focuses on developing drugs to
combat human
problems like endocrine diseases
Scott Struthers
and cancers.
At the Found Animals Foundation,
the Michelson Prize and Grants program is seeking a nonsurgical
way to sterilize dogs and cats.
The connection wasn’t immediately clear.
But the Michelson project “stuck
someplace in the back of my head”
after Struthers heard about it, and
eventually he realized there could be
a link to his firm’s work. Crinetics, a
small startup firm founded in 2010 in
San Diego, was working on an antiovarian cancer drug that might have
a side effect of rendering women
sterile. While the side effect wasn’t
an intended component for its human
applications, Struthers, the firm’s
president and chief scientific officer,
wondered if the drug might cause sterility in dogs and cats.
The Michelson program awarded
Crinetics a two-year research grant of
more than $540,000. In a time when
funding is tight, Struthers credits
the Found Animals Foundation with
catching the eyes of researchers “who
are normally just thinking about humans, and making them think about
what they can do for our pets.”
While he’s not on the front lines,
Struthers says he’s learning how important a nonsurgical sterilant could
be in the battle against pet overpopulation. No matter how efficiently its
practitioners work, spaying and neutering is still a surgical procedure, he
notes. “You can only go so fast.”

Johnston: It’s not easy to completely disable the reproductive systems. In nature, the
reproductive systems have a lot of ability to
rebound, for survival of the species.
Secondly, we have mandated a thoroughly high standard in looking at both the
male and female dog and cat. Dogs and cats
are real different, and males and females are
real different, and so to give a single injection
of something that will safely and permanently
knock out their [reproductive capability] is really a big challenge.
The money is as important, perhaps,
as the other two. I’ve worked in dog and
cat reproduction for nearly 40 years now,
and people have done good research historically, all over the world, in trying to find
safe contraceptive agents. But in my career
at universities you would scramble to get
a $10,000 to $50,000 grant, and now we
are making available a quarter of a million
dollars a year for three to four years. We’re
really getting some traction in that regard;
we’ve really had some quite brilliant proposals come in that we think may be able
to solve this challenge.
What would happen if nobody wins the
$25 million prize?
Gilbreath: The grant program would continue, and it could be that we have products
that come out of grant-funded research that
do not meet all of the criteria for the prize,
but that would have an impact on the issue.
We could very well choose to commercialize
some products, for example, if [they] only
worked in cats. That could still be a very
useful product.

What’s your impression of how the
project is going so far?
Gilbreath: We’re seeing exactly what we had
hoped for, which is people that were working on technology that could be relevant, but
had no idea that this problem existed, actually having that moment of inspiration, and
saying, “Oh, this compound that I’m developing for ovarian cancer treatment kills reproductive cells, so I bet that maybe with some
tweaks, you could use it to sterilize animals,
because I know that a side effect [of] ovarian
cancer treatment is sterility.”
Are you optimistic that you’re going to
find what you’re looking for?
Johnston: I’m really optimistic. I was [initially] negative about this whole process. I
turned down a position on the board originally, because I thought it was like [saying
to] somebody, “Oh, we’ll give you $25 million to turn lead into gold.” But I have since
come to recognize that in the last 10 to 15
years, science has advanced on so many
fronts that now I really do believe we’re
going to award this prize. AS

“It’s not necessarily our
intention to replace
surgical spay/neuter. It’s
our intention to extend
the reach to places
and to people where
surgical techniques
don’t work well now.”
— AIMEE GILBREATH
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Gilbreath: I think it’s probably a combination. Nonsurgical products for humans are
out there, and they’ve been out there for 40
years. If you can do it for humans, I have no
doubt that it is technologically possible to do
it for pets. I have to think that a lot of it has
been technology, and funding to really motivate people to apply cutting-edge technology
to that issue.

